Vaxart Stock Forecast, Price & News

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

Is Vaxart a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart or view top-rated stocks.

What stocks does MarketBeat like better than Vaxart?

Wall Street analysts have given Vaxart a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaxart wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Vaxart.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) issued its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.01. Vaxart had a negative net margin of 4,363.92% and a negative trailing twelve-month return on equity of 34.27%.
View Vaxart's earnings history.

How has Vaxart's stock been impacted by COVID-19 (Coronavirus)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 294.7% and is now trading at $8.17.
View which stocks have been most impacted by COVID-19.

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart's stock reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

3 brokers have issued 12-month price targets for Vaxart's shares. Their forecasts range from $9.00 to $18.00. On average, they expect Vaxart's share price to reach $13.33 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price.
View analysts' price targets for Vaxart or view top-rated stocks among Wall Street analysts.

Who are Vaxart's key executives?

Vaxart's management team includes the following people:

• Andrei Floroiu, President CEO, CFO & Director
• Sean N. Tucker, Chief Scientific Officer & Senior Vice President
• Richard Schwartz, Senior Vice President-Technical Operations
• Shaily Jaini Garg, SVP-Clinical Development & Project Management
• Margaret A. Echerd, Chief Accounting Officer & Senior Vice President

Who are some of Vaxart's key competitors?

Some companies that are related to Vaxart include Sana Biotechnology (SANA), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Bavarian Nordic A/S (BVNRY), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Instil Bio (TIL), Translate Bio (TBIO), Cortexyme (CRTX), Soaring Eagle Acquisition (SRNG), BioCryst Pharmaceuticals (BCRX) and C4 Therapeutics (CCCC).
View all of VXRT's competitors.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), OrganiGram (OGI) and Novan (NOVN).

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.65%), State Street Corp (6.06%), Vanguard Group Inc. (4.78%), Geode Capital Management LLC (1.65%), Susquehanna International Group LLP (0.00%) and Northern Trust Corp (1.00%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

Which institutional investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Principal Financial Group Inc., Rafferty Asset Management LLC, FMR LLC, Bank of Montreal Can, Wells Fargo & Company MN, Bailard Inc., and National Asset Management Inc.. Company insiders that have sold Vaxart company stock in the last year include Margaret Echerd, Robert A Yedid, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart or view top insider-selling stocks.

Which institutional investors are buying Vaxart stock?

VXRT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, GMT Capital Corp, Vanguard Group Inc., Nuveen Asset Management LLC, Citadel Advisors LLC, and Charles Schwab Investment Management Inc.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, and Wouter Latour.
View insider buying and selling activity for Vaxart or or view top insider-buying stocks.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $8.17.

How much money does Vaxart make?

Vaxart has a market capitalization of $1.02 billion and generates $4.05 million in revenue each year. The biotechnology company earns $-32,220,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Vaxart have?

Vaxart employs 28 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

Where are Vaxart's headquarters?

Vaxart is headquartered at 290 Utah Ave. Suite 200, South San Francisco CA, 94080.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500 or via email at [email protected].